ArticleBMC medicine2022
Speech silence character as a diagnostic biomarker of early cognitive decline and its functional mechanism: a multicenter cross-sectional cohort study.
Article in BMC medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Diagnostic utility of speech-based biomarkers in mild cognitive impairment: a systematic review and meta-analysis.Age and ageing · 2025Pooled it
- Translation of task-evoked negative BOLD response into aging and Alzheimer's disease: a systematic review of the current literature.Journal of translational medicine · 2025Pooled it
- Assessment of Language Impairments Towards Identifying Markers for Early Diagnosis of Pathological Cognitive Decline.Behavioral sciences (Basel, Switzerland) · 2026Review
- A Machine Learning Framework for Cognitive Impairment Screening from Speech with Multimodal Large Models.Bioengineering (Basel, Switzerland) · 2026Article
- Speech digital biomarker combined with fluid biomarkers predict cognitive impairment through machine learning.Alzheimer's research & therapy · 2025Article
- The China Alzheimer Report 2025.General psychiatry · 2025Review
- Detailed Analysis of Responses from Older Adults through Natural Speech: Comparison of Questions by AI Agents and Humans.International journal of environmental research and public health · 2024Article
- Acoustic assessment in mandarin-speaking Parkinson's disease patients and disease progression monitoring and brain impairment within the speech subsystem.NPJ Parkinson's disease · 2024Review
- Harnessing Speech-Derived Digital Biomarkers to Detect and Quantify Cognitive Decline Severity in Older Adults.Gerontology · 2024Article
- Article
- Consensus on rapid screening for prodromal Alzheimer's disease in China.General psychiatry · 2024Review
- Screening for early Alzheimer's disease: enhancing diagnosis with linguistic features and biomarkers.Frontiers in aging neuroscience · 2024Article
- Harnessing acoustic speech parameters to decipher amyloid status in individuals with mild cognitive impairment.Frontiers in neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundLanguage deficits frequently occur during the prodromal stages of Alzheimer's disease (AD). However, the characteristics of linguistic impairment and its underlying mechanism(s) remain to be explored for the early diagnosis of AD.
methodsThe percentage of silence duration (PSD) of 324 subjects was analyzed, including patients with AD, amnestic mild cognitive impairment (aMCI), and normal controls (NC) recruited from the China multi-center cohort, and the diagnostic efficiency was replicated from the Pitt center cohort. Furthermore, the specific language network involved in the fragmented speech was analyzed using task-based functional magnetic resonance.
resultsIn the China cohort, PSD increased significantly in aMCI and AD patients. The area under the curve of the receiver operating characteristic curves is 0.74, 0.84, and 0.80 in the classification of NC/aMCI, NC/AD, and NC/aMCI+AD. In the Pitt center cohort, PSD was verified as a reliable diagnosis biomarker to differentiate mild AD patients from NC. Next, in response to fluency tasks, clusters in the bilateral inferior frontal gyrus, precentral gyrus, left inferior temporal gyrus, and inferior parietal lobule deactivated markedly in the aMCI/AD group (cluster-level P < 0.05, family-wise error (FWE) corrected). In the patient group (AD+aMCI), higher activation level of the right pars triangularis was associated with higher PSD in in both semantic and phonemic tasks.
conclusionsPSD is a reliable diagnostic biomarker for the early stage of AD and aMCI. At as early as aMCI phase, the brain response to fluency tasks was inhibited markedly, partly explaining why PSD was elevated simultaneously.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.